Birchview Capital’s Protagonist Therapeutics PTGX Stock Holding History

Birchview Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.29M	Buy	35,018 +18	+0.1%	+$1.88K	2.01%	14
2026 Q1	$3.69M	Sell	35,000 -20,000	-36%	-$1.77M	2.1%	13
2025 Q4	$4.8M	Buy	55,000 +7,000	+15%	+$573K	2.81%	8
2025 Q3	$3.19M	Hold	48,000	–	–	2.41%	10
2025 Q2	$2.65M	Sell	48,000 -2	-0%	-$96	2.63%	9
2025 Q1	$2.32M	Buy	48,002 +2	+0%	+$84	2.02%	12
2024 Q4	$1.85M	Hold	48,000	–	–	1.51%	19
2024 Q3	$2.16M	Hold	48,000	–	–	1.87%	15
2024 Q2	$1.66M	Hold	48,000	–	–	1.54%	18
2024 Q1	$1.39M	Hold	48,000	–	–	1.13%	20
2023 Q4	$1.1M	Buy	48,000 +10,000	+26%	+$175K	0.86%	25
2023 Q3	$634K	Hold	38,000	–	–	0.54%	31
2023 Q2	$1.05M	Hold	38,000	–	–	0.79%	23
2023 Q1	$874K	Hold	38,000	–	–	0.68%	23
2022 Q4	$415K	Hold	38,000	–	–	0.29%	37
2022 Q3	$320K	Hold	38,000	–	–	0.23%	47
2022 Q2	$301K	Hold	38,000	–	–	0.22%	47
2022 Q1	$900K	Hold	38,000	–	–	0.65%	30
2021 Q4	$1.3M	Hold	38,000	–	–	0.84%	23
2021 Q3	$673K	Buy	38,000 +28,000	+280%	+$1.19M	0.46%	35
2021 Q2	$449K	Hold	10,000	–	–	0.27%	45
2021 Q1	$259K	Buy	+10,000	New	+$253K	0.15%	49

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Birchview Capital's PTGX Position: Q2 2026 in Review

Birchview Capital increased its Protagonist Therapeutics (PTGX) stake by 0.05% in Q2 2026, buying an estimated $1.88K and bringing the position to 35,018 shares worth $4.29M. The position accounts for 2.01% of the portfolio, ranked #14.

Birchview Capital first reported a position in PTGX in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.8M in Q4 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Birchview Capital held 35,018 shares of Protagonist Therapeutics worth $4.29M as of Q2 2026.
Birchview Capital bought 18 Protagonist Therapeutics shares in Q2 2026, an estimated $1.88K.
Protagonist Therapeutics made up 2.01% of Birchview Capital's portfolio in Q2 2026, its #14 holding.
Birchview Capital first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 22 quarters since.
Birchview Capital's Protagonist Therapeutics position peaked at $4.8M in Q4 2025.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.